CTRI/2022/02/039895尚未招募未知
COMPARISON OF SAFETY AND EFFICACY OF FLUTICASONE FUROATE/VILANTEROL VERSUS FLUTICASONE FUROATE/SALMETEROL IN THE TREATMENT OF MODERATE STABLE COPD PATIENTS - A RANDOMIZED CONTROLLED TRIA
SRM college of pharmacy0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •subjects with clinical history of moderate copd in accordance with the following definition by the european respiratory society.
- •subjects with measured FEV1/FVC ratio of 0.70 at screening.
- •subjects with measured FEVI 70% of predicted normal values.
- •patient willing to participate in the study and providing informed consent.
排除标准
- •patients with <30 and >70 years of age and women of reproductive age (15-45 years).
- •patients with symptoms of acute exacerbation.
- •patients with uncontrolled diabetes mellitus and hypertension.
- •patients on immunosuppressive drugs.
- •patients with known trigger factors of asthma and malignancy.
研究者
相似试验
尚未招募
4 期
Efficacy and safety of Fluticasone furoate with montelukast vs Fluticasone furoate with Cetirizine in patients with allergic rhinitisCTRI/2023/10/059253SRM institute of science and technology
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000